{
    "organizations": [],
    "uuid": "0aa4398336f5db2844eb4a39d6d51af16e7fb7d4",
    "author": "",
    "url": "https://www.reuters.com/article/brief-minerva-neurosciences-screens-firs/brief-minerva-neurosciences-screens-first-patient-in-phase-2b-trial-ofmin-117-to-treat-major-depressive-disorder-idUSASC09V9F",
    "ord_in_thread": 0,
    "title": "BRIEF-Minerva Neurosciences Screens First Patient In Phase 2B Trial Of Min 117 To Treat Major Depressive Disorder",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 9, 2018 / 1:10 PM / Updated 6 minutes ago BRIEF-Minerva Neurosciences Screens First Patient In Phase 2B Trial Of Min 117 To Treat Major Depressive Disorder Reuters Staff 1 Min Read \nApril 9 (Reuters) - Minerva Neurosciences Inc: \n* MINERVA NEUROSCIENCES SCREENS FIRST PATIENT IN PHASE 2B TRIAL OF MIN 117 TO TREAT MAJOR DEPRESSIVE DISORDER \n* 117 ARE EXPECTED IN FIRST HALF OF 2019 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)",
    "published": "2018-04-09T16:09:00.000+03:00",
    "crawled": "2018-04-09T16:22:06.011+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "pm",
        "updated",
        "minute",
        "ago",
        "neuroscience",
        "screen",
        "first",
        "patient",
        "phase",
        "2b",
        "trial",
        "min",
        "treat",
        "major",
        "depressive",
        "disorder",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "minerva",
        "neuroscience",
        "inc",
        "minerva",
        "neuroscience",
        "screen",
        "first",
        "patient",
        "phase",
        "2b",
        "trial",
        "min",
        "treat",
        "major",
        "depressive",
        "disorder",
        "expected",
        "first",
        "half",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}